Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

This is a Phase I/II, open-label dose-escalation study designed to evaluate the maximum tolerated dose (MTD) and dose-limiting side effects of ibrutinib (560 or 840 or 420 mg daily oral dose), given in combination with trastuzumab administered through the vein, in patients with HER2-amplified Metastatic Breast Cancer that has gotten …

cancer
breast cancer
muga scan
mammogram
erbb2
  • 36 views
  • 10 Mar, 2021
  • 1 location
Tolebrutinib a Brain-penetrant Bruton s Tyrosine Kinase Inhibitor for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

Background Some multiple sclerosis (MS) lesions stay inflamed for very long periods of time. This type of inflammation is not affected by any MS medications. These lesions can lead to slow worsening of MS symptoms. Researchers want to see if a new drug can help. Objective To see if tolebrutinib …

rituximab
MRI
ocrelizumab
  • 0 views
  • 28 Jul, 2021
  • 1 location
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Background Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate. Objective To …

cancer
da-epoch
diffuse large b-cell lymphoma
etoposide
prednisone
  • 0 views
  • 09 May, 2021
  • 1 location
RMS Study of BTK Inhibitor SAR442168

To access SAR442168 in the RMS populstion. Efficaty will be accessed by adjudicated relapse rate, disability progression, and MRI findings of disease activity.

  • 0 views
  • 21 Jul, 2021
  • 1 location